<DOC>
	<DOC>NCT00988598</DOC>
	<brief_summary>The purpose of the study is to evaluate the safety of PF-04447943 when given in combination with donepezil in subjects who have Alzheimer's Disease. The study will also evaluate the absorption and distribution of both PF-04447943 and donepezil.</brief_summary>
	<brief_title>A Brief Study To Evaluate The Safety, Tolerability, And Blood Levels Of Multiple Doses Of PF-044467943 Or Placebo In Combination With Donepezil In Subjects With Mild To Moderate Alzheimer's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Subjects must have Alzheimer's dementia with a Mini Mental State Examination score between 1826, inclusive. Subjects must have a reliable caregiver. Subjects must be on Aricept Memantine is allowed if subjects are on a stable dose Subjects must be in reasonably good health, based on medical history, physical examination, vital signs, and ECG, with no serious or unstable disease within the past 3 months. Subjects with clinically significant heart disease cannot participate. Subjects with a past or current history of seizures cannot participate.</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>phase 1 Alzheimer's disease donepezil</keyword>
</DOC>